Case Report: Osimertinib-induced acute interstitial lung disease
Osimertinib is a third-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively targets EGFR-TKI-sensitive mutations, thereby inhibiting tumor cell proliferation, migration, and invasion. Herein, we present a case of osimertinib-induced interstit...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1608733/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849471287936679936 |
|---|---|
| author | Zhiwu Lin Liang Wu Yang Yu Jiudong Jiang Yanchun Yang Guibao Xiao |
| author_facet | Zhiwu Lin Liang Wu Yang Yu Jiudong Jiang Yanchun Yang Guibao Xiao |
| author_sort | Zhiwu Lin |
| collection | DOAJ |
| description | Osimertinib is a third-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively targets EGFR-TKI-sensitive mutations, thereby inhibiting tumor cell proliferation, migration, and invasion. Herein, we present a case of osimertinib-induced interstitial lung disease (ILD) in an 80-year-old woman with EGFR-mutated lung adenocarcinoma. The patient was treated with osimertinib as first-line therapy for metastatic non-small cell lung cancer (NSCLC). On day 45 of treatment, she experienced acute onset of severe dyspnea, which rapidly progressed to diffuse bilateral pulmonary consolidation and profound hypoxemia. Despite discontinuation of osimertinib and administration of aggressive supportive care, her clinical condition continued to deteriorate, ultimately resulting in a fatal outcome. This case underscores the importance of monitoring respiratory symptoms in patients receiving EGFR-TKIs, promptly diagnosing ILD, and implementing early intervention to mitigate adverse outcomes. |
| format | Article |
| id | doaj-art-b1b6765b499e4aaeacf7b8e5c220d68d |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-b1b6765b499e4aaeacf7b8e5c220d68d2025-08-20T03:24:52ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-06-011610.3389/fphar.2025.16087331608733Case Report: Osimertinib-induced acute interstitial lung diseaseZhiwu Lin0Liang Wu1Yang Yu2Jiudong Jiang3Yanchun Yang4Guibao Xiao5Department of Thoracic Surgery, Ziyang Central Hospital, Ziyang, ChinaDepartment of Thoracic Surgery, Ziyang Central Hospital, Ziyang, ChinaDepartment of Thoracic Surgery, Ziyang Central Hospital, Ziyang, ChinaDepartment of Thoracic Surgery, Ziyang Central Hospital, Ziyang, ChinaDepartment of Thoracic Surgery, Ziyang Central Hospital, Ziyang, ChinaDepartment of Infectious Diseases, Ziyang Central Hospital, Ziyang, ChinaOsimertinib is a third-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively targets EGFR-TKI-sensitive mutations, thereby inhibiting tumor cell proliferation, migration, and invasion. Herein, we present a case of osimertinib-induced interstitial lung disease (ILD) in an 80-year-old woman with EGFR-mutated lung adenocarcinoma. The patient was treated with osimertinib as first-line therapy for metastatic non-small cell lung cancer (NSCLC). On day 45 of treatment, she experienced acute onset of severe dyspnea, which rapidly progressed to diffuse bilateral pulmonary consolidation and profound hypoxemia. Despite discontinuation of osimertinib and administration of aggressive supportive care, her clinical condition continued to deteriorate, ultimately resulting in a fatal outcome. This case underscores the importance of monitoring respiratory symptoms in patients receiving EGFR-TKIs, promptly diagnosing ILD, and implementing early intervention to mitigate adverse outcomes.https://www.frontiersin.org/articles/10.3389/fphar.2025.1608733/fulladverse drug reactionosimertinibinterstitial lung diseaselung cancerEGFR-TKI |
| spellingShingle | Zhiwu Lin Liang Wu Yang Yu Jiudong Jiang Yanchun Yang Guibao Xiao Case Report: Osimertinib-induced acute interstitial lung disease Frontiers in Pharmacology adverse drug reaction osimertinib interstitial lung disease lung cancer EGFR-TKI |
| title | Case Report: Osimertinib-induced acute interstitial lung disease |
| title_full | Case Report: Osimertinib-induced acute interstitial lung disease |
| title_fullStr | Case Report: Osimertinib-induced acute interstitial lung disease |
| title_full_unstemmed | Case Report: Osimertinib-induced acute interstitial lung disease |
| title_short | Case Report: Osimertinib-induced acute interstitial lung disease |
| title_sort | case report osimertinib induced acute interstitial lung disease |
| topic | adverse drug reaction osimertinib interstitial lung disease lung cancer EGFR-TKI |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1608733/full |
| work_keys_str_mv | AT zhiwulin casereportosimertinibinducedacuteinterstitiallungdisease AT liangwu casereportosimertinibinducedacuteinterstitiallungdisease AT yangyu casereportosimertinibinducedacuteinterstitiallungdisease AT jiudongjiang casereportosimertinibinducedacuteinterstitiallungdisease AT yanchunyang casereportosimertinibinducedacuteinterstitiallungdisease AT guibaoxiao casereportosimertinibinducedacuteinterstitiallungdisease |